相关实验视频
Updated: Jun 4, 2025

A Porcine Model of Acute Autologous Pulmonary Embolism
Published on: September 6, 2024
肺栓塞患者同时患有COVID-19并接受延长抗凝剂的出血风险:一个多中心队列研究
Yishan Li1, Linfeng Xi2, Dingyi Wang3
1The First Clinical Medical College, Shanxi Medical University, Taiyuan, China; National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.
冠状病毒病2019 (COVID-19) 和长期COVID显著增加了肺栓塞 (PE) 患者在延长抗凝固治疗中的出血风险. 密切监测和优化抗凝药对这些患者至关重要.
科学领域:
- 心脏病学 心脏病学
- 传染性疾病 传染性疾病
- 肺部病理学 肺部病理学
背景情况:
- 冠状病毒病2019 (COVID-19) 对接受延长抗凝治疗的肺栓塞 (PE) 患者的临床影响尚不清楚.
- 奥米克朗疫情对这些患者的特定影响需要进一步调查.
研究的目的:
- 调查Omicron疫情对接受延长抗凝治疗的PE患者的影响.
- 评估COVID-19,长期COVID和临床结果之间的关联,特别是出血事件和VTE复发.
主要方法:
- 在Omicron大流行期间进行的一项前性多中心队列研究.
- 招募在2016年1月至2022年9月期间接受延长抗凝治疗的PE患者.
- 倾向性得分权重与重叠权重 (PSOW) 分析以比较COVID-19和非COVID-19组之间的结果.
主要成果:
- 与非COVID-19患者相比,COVID-19患者的出血率显著更高 (10.5%vs2.1%),在PSOW (OR=4.79) 后持续存在.
- 两组之间没有观察到VTE复发的显著差异.
- 长期的COVID与更高的出血率 (14.6%对3.5%) 和PSOW (HR=3.29) 后增加的出血风险有关.
- 活跃的恶性瘤,慢性病和急性COVID-19出血预测了长期COVID患者的出血.
结论:
- 无论是COVID-19还是长期COVID都与长期抗凝药治疗PE患者的出血风险增加有关.
- 这些发现强调了对这种患者群体进行警监测和量身定制的抗凝策略的必要性.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Pneumothorax-I
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Pneumothorax-II
Clinical Manifestations:
Epistaxis
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...

